Brege Laura 4

4 · ACADIA PHARMACEUTICALS INC · Filed Jun 1, 2026

AI-generated summary of this filing

Updated Jun 1, 2026

ACADIA (ACAD) Director Laura Brege Receives 25,315 RSUs, Exercises 8,107

What Happened

Laura Brege, a director of ACADIA PHARMACEUTICALS INC (ACAD), exercised/converted derivative rights for 8,107 shares and simultaneously had 8,107 derivative shares recorded as disposed with $0 reported proceeds. She was also granted/received two restricted stock unit (RSU) awards totaling 25,315 RSUs (16,004 + 9,311) on May 29, 2026; the grants are shown at $0.00 per share in the filing. The RSUs vested in full on May 29, 2026 (the date of the company’s annual meeting).

Key Details

Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (within typical two-business-day window).
Derivative exercise/conversion: 8,107 shares (code M). Disposition: 8,107 shares at $0.00 reported (derivative).
Grants/awards: 16,004 RSUs and 9,311 RSUs (codes A) — total 25,315 RSUs, reported at $0.00.
Shares owned after transaction: not specified in the provided filing.
Relevant footnotes from the filing:
- F1: Each RSU equals a contingent right to one common share.
- F2: The RSUs vested in full on May 29, 2026 (annual meeting date).
- F3: (Related) Stock options referenced will vest quarterly over one year following grant (final tranche earlier of one year or next annual meeting).
- F4: The RSUs will vest fully on the earlier of one year after grant or the next annual meeting; the reporting person has elected to defer receipt of the underlying shares until certain triggering events (e.g., fifth anniversary, cessation of service, or change in control).

Context

The filing shows $0 proceeds on the disposed derivative shares, which commonly reflects a net settlement or shares withheld to cover exercise/tax obligations rather than an open-market sale. The RSUs vested but the director has elected to defer actual receipt of shares under the plan’s deferral rules (per F4). These types of award vesting and net-settlement exercises are routine compensation actions and do not by themselves indicate a buy or sell sentiment.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-05-29+8,107→ 23,202 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-05-29−8,107→ 0 total
→ Common Stock (8,107 underlying)
Award
Director Stock Options (Right to Buy)
[F3]
2026-05-29+16,004→ 16,004 total
Exercise: $21.66Exp: 2036-05-28→ Common Stock (16,004 underlying)
Award
Restricted Stock Units
[F1][F4]
2026-05-29+9,311→ 9,311 total
→ Common Stock (9,311 underlying)

Footnotes (4)

[F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
[F2]The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
[F3]The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
[F4]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.

Signature

/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-06-01

1 file